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Abstract The need for an early and differential diagnosis
of Parkinson’s disease (PD) is undoubtedly one of the main
quests of the century. An early biomarker would enable
therapy to begin sooner and would, hopefully, slow or better
prevent progression of the disease. We performed transcript
profiling via quantitative RT-PCR in RNA originating
from peripheral blood samples. The groups were de novo
(n = 11) and medicated PD (n = 94) subjects and healthy
controls (n = 34), while for negative control Alzheimer’s
disease (AD; n = 14) subjects were recruited as an addi-
tional neurodegenerative disease. The results were retested
on a second recruitment consisting 22 medicated PD
subjects versus 33 controls and 12 AD. Twelve transcripts
were chosen as candidate genes, according to previous
postmortem brain profiling. Multiple analyses resulted in
four significant genes: proteasome (prosome, macropain)
subunit-alpha type-2 (PSMA2; p = 0.0002, OR = 1.15
95% CI 1.07–1.24), laminin, beta-2 (laminin S) (LAMB2;
p = 0.0078, OR = 2.26 95% CI 1.24–4.14), aldehyde
dehydrogenase 1 family-member A1 (ALDH1A1; p =
0.016, OR = 1.05 95% CI 1.01–1.1), and histone cluster-1
H3e (HIST1H3E; p = 0.03, OR = 0.975 95% CI
0.953–0.998) differentiating between medicated PD sub-
jects versus controls. Using these four biomarkers for PD
diagnosis, we achieved sensitivity and specificity of more
than 80%. These biomarkers might be specific for PD
diagnosis, since in AD subjects no significant results were
observed. In the second validation, three genes (PSMA2,
LAMB2 and ALDH1A1) demonstrated high reproducibil-
ity. This result supports previous studies of gene expression
profiling and may facilitate the development of biomarkers
for early diagnosis of PD.
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Introduction
Parkinson’s disease (PD) is a progressive neurodegenera-
tive disorder, with a prevalence of 1% in the population
aged above 65 years. The main pathophysiologic feature is
degeneration of dopaminergic neurons in the substantia
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nigra, which results in striatal dopamine deficiency
(Bernheimer et al. 1973). Nonetheless, the etiology of PD
is still elusive.
Currently, PD patients are predominantly scored with
the Unified Parkinson’s Disease Rating Scale (UPDRS)
(Fahn et al. 1987) and the modified Hoehn and Yahr
staging scale (Hoehn and Yahr 1967). The criteria of the
UK Brain Bank are employed for diagnosis (Hughes et al.
2002). Yet, even in highly specialized centers, the sensi-
tivity of the clinical diagnosis of PD in symptomatic
patients is only 91% and is likely to be lower in other
settings (Tolosa et al. 2006). Familial forms of PD exist in
about 5% of the affected population and involve mutations
in many genes, e.g. a-synuclein, LRRK2, UCLH-1, PINK1,
DJ-1 and Parkin (Hatano et al. 2009; Klein et al. 2009).
Functional imaging techniques, i.e. positron emission
tomography with [18F]-Dopa or single photon emission
tomography with [123I]-b-CIT, visualize reduced striatal
uptake of 18F-DOPA in PD or loss of dopamine trans-
porters, whereas for atypical PD variants the second option
is limited (Brooks 1998; Coste et al. 2009; Koerts et al.
2007). Even these tools (clinical diagnosis and imaging) do
not provide yet the specificity and sensitivity for PD
diagnosis as one would wish for (Jankovic et al. 2000;
Eerola et al. 2005; Kassiou et al. 2009). In addition, these
diagnostic tools are only able to detect PD subjects after
nearly 70% of the neurons have been degenerated, the
point at which symptoms appear (Bhidayasiri 2006). This
hampers treatment efforts to slow down degeneration or
even rescue neurons. The importance of biomarkers for
early diagnosis is discussed in many forms, especially as
the case today is that by the time a patient is diagnosed
with the disorder, the neurodegenerative process has been
established for many years (Postuma and Montplaisir 2006;
Paulsen 2009; Michell et al. 2004; Lovrecic et al. 2009;
Mollenhauer and Trenkwalder 2009; Ravina et al. 2009).
Hence, early diagnostic criteria are most important to allow
an early therapeutic window.
In our previous study of gene expression profiles in
postmortem brain tissue (Gru¨nblatt et al. 2004), as well as
four following studies (Hauser et al. 2005; Lu et al. 2005;
Zhang et al. 2005; Simunovic et al. 2009), four pathways
were shown to be altered in the substantia nigra of PD
subjects: chaperones, ubiquitination, vesicle trafficking, and
nuclear-encoded mitochondrial genes. Analysis of aberrant
gene expression profiles in the central nervous system
(CNS) of PD subjects cannot be accomplished during life.
This problem may be circumvented by analyzing the
peripheral tissues of PD subjects. Such an approach is
recently discussed in PD as well as other movement disor-
ders such as Huntington’s disease (Lovrecic et al. 2009;
Ravina et al. 2009). There is accumulating evidence of
systemic alterations in key cellular functions of affected
individuals (Scherzer et al. 2007; Sullivan et al. 2006;
Hurley et al. 2003).
In the present study, we applied a similar strategy and
extended our previous study in the CNS (Gru¨nblatt et al.
2004) in an attempt to discover specific biomarkers for
early diagnosis in blood. We used previous knowledge,
obtained from brain postmortem gene expression profiling
for PD, to choose candidate genes that might show patterns
for risk scoring of PD in whole blood samples. Twelve
potential transcripts were tested in early-non medicated (de
novo), as well as medicate PD subjects and compared to
healthy controls.
Methods
Subjects
The subjects gave informed consent according to the
Helsinki Declaration. The study protocol was approved by
the local ethics committee of the Universities of Wu¨rzburg,
Bochum, and the Clinic of Wiesbaden, Germany. Written
informed consent was obtained from all subjects or their
primary caregivers. Patients with sporadic PD and healthy
elderly controls without neurological disorders or dementia
were assessed (excluded patients with familial PD by
family anamnesis). As an additional control of other neu-
rodegenerative disease, we recruited patients with Alzhei-
mer’s disease (AD) who did not suffer from any other
neurological disorders. All subjects underwent formal
diagnostic procedure according to the UK Brain Bank
criteria for PD (Hughes et al. 2002). The Hoehn Yahr
staging was used for clinical evaluation of PD (Hoehn and
Yahr 1967) and the National Institute of Neurological and
Communicative Disorders and Stroke—Alzheimer’s Dis-
ease and Related Disorders Association criteria (McKhann
et al. 1984) for AD. Alzheimer’s disease assessment scale-
cognitive subscale (Wouters et al. 2008), mini-mental state
examination (MMSE) (O’Connor et al. 1989), clinical
dementia rating (CDR) (Berg 1988), UPDRS (Fahn et al.
1987), and Hamilton depression scale (Hamilton 1960)
were administered to all subjects. In addition, detailed
information on medication and smoking habits were col-
lected. Some of the subjects were retested in a second
recruitment after a period of 3–6 months from the first
recruitment.
One hundred and fifty-three subjects (66 female and 85
male) with a mean age of 63.03 ± 11.07 years participated
in the first recruitment (Table S1, Electronic Supplemen-
tary Material); 105 had PD (age 60.5 ± 10.7 years, MMSE
scores 28.50 ± 2.07, UPDRS scores 31.34 ± 18.82,
Hamilton depression scores 2.01 ± 3.86), 14 had AD (age
70.8 ± 10.2 years, MMSE scores 18.64 ± 6.06, UPDRS
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scores 9.36 ± 10.40, Hamilton depression scores 3.50 ±
3.67) and 34 were healthy controls (age 67.6 ± 9.8 years,
MMSE scores 29.47 ± 1.13, UPDRS scores 0.91 ± 1.90,
Hamilton depression scores 3.68 ± 6.79). Of the 105 PD
subjects, 11 were non-treated individuals, so called de novo
PD subjects (age 55.7 ± 11 years, MMSE scores 29.2 ±
0.87, UPDRS scores 27 ± 7.7, Hamilton depression scores
4.2 ± 7). PD patients were treated with anti-parkinsonian
standard therapy: with L-dopa and decarboxylase inhibitors
as basic treatment. Sixty-seven subjects (37 female and 30
male) with mean of age 65.67 ± 10 years were reinvesti-
gated in a second recruitment (Table S2, Electronic Sup-
plementary Material), 22 had PD (age 61.4 ± 9.3 years,
MMSE scores 28.68 ± 1.21, UPDRS scores 17.59 ±
16.48, Hamilton depression scores 3.09 ± 2.83), 12 had
AD (age 69.3 ± 10.3 years, MMSE scores 18.00 ± 6.47,
UPDRS scores 8.67 ± 10.33, Hamilton depression scores
3.17 ± 3.43) and 33 were healthy controls (age 67.2 ±
9.6 years, MMSE scores 29.55 ± 0.94, UPDRS scores
2.15 ± 5.51, Hamilton depression scores 3.33 ± 6.11).
Whole blood was collected with the PAXgene TM Blood
RNA system (Becton–Dickinson GmbH, Heidelberg,
Germany). The blood samples were frozen at -20C until
further processing for total RNA isolation.
Total RNA extraction
Total RNA was prepared with the PAXgeneTM Blood RNA
Kit 50 (PreAnalytiX, Qiagen and BD, Germany). RNA
isolation reagents were prepared from 0.2 lM filtered,
diethyl pyrocarbonate-treated water (Fermentas Inc., Han-
over, MD, USA) throughout the isolation procedure. Total
RNA samples were spectrophotometrically scanned
(Experion, BioRad Co., Hercules, CA, USA) from 220
to 320 nm; the A260/A280 of total RNA was typically
[1.9.
Quantitative real-time RT-PCR analysis
Quantitative real-time RT-PCR was conducted for 12
genes (Table S3, Electronic Supplementary Material): heat
shock 70 kDa protein 8 (HSPA8); proteasome (prosome,
macropain) subunit, alpha type, 2 (PSMA2); proteasome
(prosome, macropain) subunit, alpha type, 3 (PSMA3);
proteasome (prosome, macropain) subunit, alpha type, 5
(PSMA5); heparan sulfate (glucosamine) 3-O-sulfotrans-
ferase 2 (HS3ST2); solute carrier family 31 (copper
transporters), member 2 (SLC31A2); laminin, beta 2
(laminin S) (LAMB2); aldehyde dehydrogenase 1 family,
member A1 (ALDH1A1); ubiquitin-conjugating enzyme
E2K (UBC1 homolog, yeast) (HIP2); c-src tyrosine kinase
(CSK); Cannabinoid receptor 2 (CNR2); Histone cluster 1,
H3e (HIST1H3E); and 6 house-keeping genes (used as
internal controls). Total RNA (500 ng) from each sample
was reverse transcribed with the random hexamer and
oligo-dT primer mix using iScript (BioRad Co., Hercules,
CA, USA). Quantitative real-time PCR was performed in
the iCycler iQ system (BioRad Co., Hercules, CA, USA) as
described previously (Gru¨nblatt et al. 2007). The genes
were normalized to the six house-keeping genes according
to GeNorm (Vandesompele et al. 2002). Real-time PCR
was subjected to PCR amplification as described previously
(Gru¨nblatt et al. 2009). All PCR reactions were run in
duplicate. The amplified transcripts were quantified using
the comparative CT method analyzed with the BioRad
iCycler iQ system program. The same procedure was used
for baseline samples as well as the follow-up confirmation
study. Data were analyzed with Microsoft Excel 2000 to
generate raw expression values.
Statistical analysis
For the first recruitment, mean, standard deviation (SD),
median, minimum, and maximum values were calculated for
the continuous variables (Table S1, Electronic Supplemen-
tary Material). In the text, continuous variables are described
as mean ± SD. For the data of the first recruitment, uni-
variate logistic regression analyses were calculated for each
of the 12 genes and the factors gender, age, CDR, MMSE,
UPDRS, and Hamilton depression scale scores comparing
the diagnosed PD subjects to healthy subjects. p values, odds
ratios (OR), their corresponding 95% confidence intervals
(95% CI), and the areas under the receiver operating char-
acteristic curve (AUC) were calculated. Due to the small
units the OR of the raw values are partly very large (e.g.,
OR = 1596047391). Thus, we presented the ORs for the
data as multiplied with 100. All genes and co-variables
(gender and age) with a p value \0.00357 (0.05/14: Bon-
ferroni adjustment for multiplicity) were further considered
in a stepwise multiple logistic regression model. To avoid
multicollinearity, a correlation of R [ 0.6 between two
variables in the resulting model was not tolerated. The same
approach was chosen for the analysis of AD versus healthy
subjects (here, since no significant result was found in the
logistic regression, no multiple model was calculated).
Correlation analyses were performed between genes and the
factors gender, age, CDR, MMSE, UPDRS and Hamilton
depression scale scores. p values \0.008 were considered
significant (Bonferroni adjustment).
To investigate the validity of the gene measurements,
Pearson correlation coefficients were calculated for the
values of the first and the second recruitment (only for PD
and healthy subjects). Intraclass correlation coefficients
were calculated for the values of the first and second
recruitment (for all groups). p values\0.0042 were consid-
ered significant (Bonferroni adjustment). All computations
Biomarkers for Parkinson’s disease 1389
123
were completed using the statistical computing environment
R version 2.8 (http://www.r-project.org/, Department of
Statistics and Mathematics of the WU Vienna, Austria) and
SAS 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
Logistic regression was conducted for all 12 genes and co-
variables for PD versus control subjects. The p values, ORs
(given for one hundredth of the measurements), and AUCs
for the analysis of PD versus controls are presented in
Table 1. The genes PSMA2, PSMA3, SLC31A2, LAMB2,
ALDH1A1, and HIP2 significantly increased the risk for
PD diagnosis, while HIST1H3E significantly decreased the
risk for PD diagnosis. Increased UPDRS scores were sig-
nificantly associated with increased risk of PD diagnosis.
All genes or risk factors with p values \0.00357 were
further selected for multiple analysis (genes, gender, and
age). The model identified the following significant genes:
PSMA2 (p = 0.0002, OR = 1.15 95% CI 1.07–1.24),
LAMB2 (p = 0.0078, OR = 2.26 95% CI 1.24–4.14),
ALDH1A1 (p = 0.016, OR = 1.05 95% CI 1.01–1.1), and
HIST1H3E (p = 0.03, OR = 0.975 95% CI 0.953–0.998)
for PD versus control. The receiver operating characteristic
(ROC) curve was built with these four significant gene
biomarkers (Fig. 1; max rescaled R2 = 0.62, AUC =
0.92). Using these four biomarkers for PD diagnosis, we
achieved sensitivity and specificity of more than 80% (e.g.
91.5% sensitivity and 82% specificity). It must be noted
that there are more than 50 possible models out of the set of
univariate significant genes with an AUC larger than 0.87
and excluded correlations[0.6 between the variables in the
model. All these models have similar sensitivity and
specificity of more than 80%.
Correlation analysis between the genes and the factors
age, gender, MMSE, CDR, Hamilton depression scale, and
UPDRS scores resulted in some significant correlations
between the four genes (PSMA2, LAMB2, ALDH1A1, and
HIST1H3E) and the parameters, age, MMSE, and UPDRS
scores (Table 2; for all 12 genes see Tables S4 and S5,
Electronic Supplementary Material). Increased age and
UPDRS scores correlated significantly with the PSMA2
gene expression profile (decreased expression and increased
expression, respectively). Nominal significance was found
between MMSE scores and LAMB2 (increased expression
with decreased score), age and ALDH1A1 (decreased
expression with increased age), and UPDRS score and
HIST1H3E (decreased expression with increased score).
Post hoc comparison of PSMA2, LAMB2, ALDH1A1,
and HIST1H3E expression profiles between the 11 de novo
PD subjects and the other 94 medicated PD subjects yiel-
ded a significant difference only for LAMB2; the expres-
sion profile of LAMB2 mRNA in the de novo PD subjects
was lower than the medicated PD subjects (t-test:
p \ 0.0001; Table S5, Electronic Supplementary Material).
Hoehn–Yahr scores (H&Y) were slightly lower in de novo
PD (H&Y = 2.00 ± 0.50) subjects in comparison to the
other PD subjects (H&Y = 2.43 ± 0.83; Wilcoxon-test:
p = 0.05; Table S6, Electronic Supplementary Material).Table 1 Logistic regression: PD versus control
Gene p value Adjusted
p value
OR (95% CI) AUC
HSPA8 0.014 0.24 1.04 (1.01–1.07) 0.674
PSMA5 0.475 1 1.01 (0.98–1.03) 0.614
PSMA2 2.68E-05 0.00037 1.24 (1.15–1.33) 0.872
PSMA3 0.002 0.028 1.06 (1.02–1.1) 0.714
HS3ST2 0.505 1 1.08 (0.86–1.36) 0.524
SLC31A2 2.00E-05 0.00028 1.12 (1.06–1.18) 0.847
LAMB2 0.00039 0.0055 2.54 (1.52–4.26) 0.825
ALDH1A1 5.00E-05 0.0007 1.07 (1.03–1.1) 0.758
HIP2 0.00014 0.0020 1.05 (1.03–1.08) 0.743
CSK 0.004 0.056 1.03 (1.01–1.06) 0.742
CNR2 0.231 1 0.99 (0.97–1.01) 0.546
HIST1H3E 0.001 0.014 0.97 (0.96–0.99) 0.72
Gender 0.013 0.182 2.76 (1.24–6.14) 0.624
Age 0.002 0.028 0.93 (0.89–0.97) 0.666
For all parameters calculated in the regression, the OR refers to the
higher value of the parameter. The adjusted p value, is the Bonferroni
corrected p value, significance was set at p \ 0.05
OR odds ratio, CI confidence interval, AUC area under the receiver
operating characteristic curve, Gender females = 0 and males = 1
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Fig. 1 ROC curve for the four biomarkers for PD diagnosis, PSMA2,
LAMB2, ALDH1A1 and HIST1H3E
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Validation analysis was conducted using 67 subjects (37
female and 30 male) with a mean age of 65.67 ± 10 years
who were reinvestigated in a second recruitment of PD, AD
and healthy control subjects (Table S2, Electronic Supple-
mentary Material). Correlation analyses were calculated to
obtain a measure for the reproducibility of the gene mea-
surements conducted for the first recruitment. Some genes
showed high reproducibility (Table 3; for intraclass correla-
tion see Table S7, Electronic Supplementary Material), e.g.,
three genes from the multiple models for PD versus healthy
(PSMA2, LAMB2, and ALDH1A1). Two genes showed only
nominal significance for reproducibility (PSMA3 and
CNR2), while two genes (HS3ST2 and HIST1H3E) had low
reproducibility rates. For the second recruitment, a multiple
model including the variables PSMA2, LAMB2, ALDH1A1,
and HIST1H3E was used to calculate the AUC (max rescaled
R2 = 0.66, AUC = 0.93) which resulted in sensitivity and
specificity of more than 80%.
Discussion
We found that the combination of four gene profiles in
whole blood might be of diagnostic value for estimating the
risk of developing sporadic PD. Since sporadic PD is a
complex neurodegenerative disease, it is expected that a
complex diagnostic tool with more than one marker is
necessary (Fasano et al. 2008). Adding to the complexity of
the disease classification, considerable overlap is seen at
Table 2 Correlations between
genes and factors
The adjusted p value, is the
Bonferroni corrected p value,
significance was set at p \ 0.05.
Significant results are indicated
in Bold
Gene Factor Correlation
coefficient
p value Adjusted
p value
PSMA2 Age -0.274 0.001 0.006
MMSE -0.149 0.08 0.48
UPDRS score 0.331 <0.001 <0.001
CDR score -0.102 0.231 1
Hamilton depression score -0.186 0.059 0.354
Gender 0.035 0.258 1
LAMB2 Age -0.077 0.37 1
MMSE -0.235 0.005 0.03
UPDRS score 0.101 0.239 1
CDR score 0.157 0.065 0.36
Hamilton depression score 0.121 0.22 1
Gender 0.167 0.558 1
ALDH1A1 Age -0.238 0.005 0.03
MMSE 0.059 0.489 1
UPDRS score 0.12 0.16 0.96
CDR score -0.109 0.203 1
Hamilton depression score -0.045 0.647 1
Gender 0.159 0.066 0.396
HIST1H3E Age 0.15 0.084 0.504
MMSE 0.038 0.666 1
UPDRS score -0.189 0.029 0.175
CDR score 0.176 0.042 0.252
Hamilton depression score 0.012 0.905 1
Gender -0.005 0.53 1
Table 3 Correlation between first and second recruitment
Gene Correlation
coefficient
p value Adjusted
p value
HSPA8 0.605 1.02E203 0.0122
PSMA5 0.479 0.00021 0.0025
PSMA2 0.566 6.68E203 0.0801
PSMA3 0.294 0.029 0.348
HS3ST2 0.073 0.596 1
SLC31A2 0.57 5.50E206 6.6E205
LAMB2 0.58 3.40E206 4.08E205
ALDH1A1 0.447 0.001 0.012
HIP2 0.744 8.00E211 9.6E210
CSK 0.478 0.00022 0.0026
CNR2 0.277 0.043 0.516
HIST1H3E 0.252 0.066 0.792
The adjusted p value, is the Bonferroni corrected p value, significance
was set at p \ 0.05. Significant results are indicated in bold
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autopsy between patients clinically diagnosed with PD and
those clinically diagnosed with other neurodegenerative
diseases, i.e. sporadic AD (Gru¨nblatt 2008).
As described by Fasano and colleagues (2008), as well
as by Scherzer (2009), a multiple biomarker combination
may be used for early diagnosis of PD. In the current study,
we showed the combination of four biomarkers gave high
sensitivity and specificity, which indicates the potential of
such biomarkers to identify the risk of developing PD.
Three of the genes were not influenced by PD medication,
since no significant differences were observed between de
novo PD subjects and medicated PD subjects. LAMB2
mRNA levels in de novo PD subjects were significant
lower than treated PD subjects, while the expression was
higher compared to controls; this might point to the disease
progression, as well as treatment effects. One bias in the
four biomarker model is the poor reproducibility of the
HIST1H3E gene. But even when this gene is omitted and
the three biomarkers are used in the multiple models, high
specificity and sensitivity with AUC of 0.91 are found.
Using multiple model analysis, we actually could find
several models for biomarker batches that gave similar
specificity and sensitivity. This might point to the com-
plexity of such neurodegenerative diseases with regard to
the cause of neurodegeneration and progress, as described
by Hennecke and Scherzer (2008). Our choice of these four
biomarkers for PD diagnosis is strengthened by the speci-
ficity to sporadic PD, as no significant association was
found to link these biomarkers with sporadic AD subjects
(Table S8, Electronic Supplementary Material).
Similar to our previous publication using microarray
technology for a biomarker search in blood samples
(Gru¨nblatt et al. 2004), we showed a combination of gene
expression profiles in cellular blood and linked clinical data
can rapidly characterize candidate laboratory biomarkers of
PD risk. Recently, Bogdanov et al. (2008) reported prom-
ising use of metabolomic blood biomarkers for PD diag-
nosis that may provide both diagnosis as well as
monitoring disease progression in PD. Scherzer et al.
(2007) described a biomarker search in whole blood from
early stage PD subjects using microarray screening. In their
study, they found eight biomarker genes that might be used
as markers for risk scoring of PD. Out of the eight bio-
markers, two similar genes were investigated in our study,
the HIP and HSPA8 which is related to the ST13. Both
genes significantly altered its expression in PD at the first
and second recruitment, similar to Scherzers’ report. Risk
markers for complex diseases such as PD are not simply
present or absent, rather they have a wide range of values
that overlap in individuals (Manolio 2003). The risk typi-
cally increases progressively with rising levels. In our
study, we searched for candidate genes based on our results
from previous microarray studies with postmortem brain
tissue (Gru¨nblatt et al. 2004). We could not show any
correlation when comparing the expression profile altera-
tions between PD and controls in blood samples to post-
mortem tissue (Gru¨nblatt et al. 2004). This does not
indicate a flaw as transcription may be altered in peripheral
blood cells by many factors such as copy number variations
in the genome, epigenetic changes such as histone modi-
fications, environmental changes causing biological pro-
cesses such as mitochondria dysfunction, genetic and
environmental changes, or as a response to brain pathology
(Hennecke and Scherzer 2008).
In conclusion, we showed the potential of peripheral
blood cell biomarkers as a tool for early diagnosis of PD.
Further investigation in a larger independent population
including different neurodegenerative disorders for differ-
entiation is required also including familial analysis of
different genetic backgrounds (e.g. glucocerebroside and
a-synuclein) to evaluate these biomarkers as potential
diagnostic biomarkers as well as therapeutic targets for
slowing the disease progression or even rescuing the
neurons.
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